Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of ALK-N001 for injection in advanced solid tumors
CTR20261097Phase 2Active
- Sponsor
- Zhejiang Anglikang Pharmaceutical
- Start
- Jun 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of QHL-1618 in Nonhematologic neoplasms, bronchial carcinoma, breast cancer and 5 more (2 arms), sponsored by Zhejiang Anglikang Pharmaceutical. Primary endpoint: Objective response rate. Started Jun 2026; status: active.
02
Drugs
QHL-1618
03
Conditions
Nonhematologic neoplasmsbronchial carcinomabreast cancerovarian cancerCervical Cancer (CC)
Beyond the preview
Go deeper on CTR20261097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261097.